Julien Edeline

47PUBLICATIONS
150CO-AUTHORS
Molecular targetsCardiology (incl. cardiovascular diseases)Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Apr 29, 2026
Impact of Child Pugh B Stage for the Treatment of Advanced HCC.

|Mar 02, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Richard S Finn, Masatoshi Kudo, Ivan Borbath

|Feb 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Stephen L Chan, Thomas Yau, Robin K Kelley

|Feb 16, 2026
Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients.

Itzel Rivera, Heloïse Bourien, Ewan Morel-Corlu

|Dec 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Jesus M Banales, Pedro M Rodrigues, Silvia Affò

Pageof 8

Frequent Collaborators

8 joint publications

Juan W Valle

6 joint publications

David Malka

5 joint publications

Anthony Turpin

5 joint publications

David Tougeron